Corrigendum
J Comp Eff Res. 2024 Feb;13(2):e240003c1. doi: 10.57264/cer-2024-0003c1. Epub 2024 Jan 16.NO ABSTRACTPMID:38226946 | DOI:10.57264/cer-2024-0003c1 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - January 16, 2024 Category: General Medicine Source Type: research

Smart connected insulin dose monitoring technologies versus standard of care: a Canadian cost-effectiveness analysis
Conclusion: For adults with T1DM in Canada, a connected insulin pen device is likely to be a cost-effective treatment option associated with greater clinical benefits and lower costs relative to a standard re-usable or disposable pen.PMID:38205726 | DOI:10.57264/cer-2023-0124 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - January 11, 2024 Category: General Medicine Authors: Katalina Chan K åre Hansen Sergey Muratov Shoghag Khoudigian Mark Lamotte Source Type: research

Radiofrequency ablation using the ThermoCool SmartTouch Catheter guided by ablation index versus antiarrhythmic drugs in atrial fibrillation treatment in China: a cost-consequence analysis
Conclusion: Radiofrequency catheter ablation using SmartTouch catheter guided by Ablation Index was superior to AADs as the first-line AF treatment in Chinese setting with better clinical outcomes and at lower costs over a 10-year time horizon.PMID:38205729 | PMC:PMC10842291 | DOI:10.57264/cer-2023-0035 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - January 11, 2024 Category: General Medicine Authors: Biqi Zhang Jie Han Dongchen Zhou Jiajia Jiang Jiawei Zhong Yunlong Lu Chenyu Zuo Xingwei Lu Jianwei Xuan Aohan Zu Yuxian He Xingang Sun Lu Chen Liangrong Zheng Source Type: research

Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers
J Comp Eff Res. 2024 Jan 11:e230147. doi: 10.57264/cer-2023-0147. Online ahead of print.ABSTRACTDevelopment of medicines in rare oncologic patient populations are growing, but well-powered randomized controlled trials are typically extremely challenging or unethical to conduct in such settings. External control arms using real-world data are increasingly used to supplement clinical trial evidence where no or little control arm data exists. The construction of an external control arm should always aim to match the population, treatment settings and outcome measurements of the corresponding treatment arm. Yet, external real-...
Source: Journal of Comparative Effectiveness Research - January 11, 2024 Category: General Medicine Authors: Kristian Thorlund Stephen Duffield Sanjay Popat Sreeram Ramagopalan Alind Gupta Grace Hsu Paul Arora Vivek Subbiah Source Type: research

R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 14
J Comp Eff Res. 2024 Jan;13(1):e230189. doi: 10.57264/cer-2023-0189. Epub 2024 Jan 4.ABSTRACTIn this latest update we highlight: a publication from the US FDA regarding the definitions of real-world data (RWD) and real-world evidence (RWE); a publication from academic researchers on a demonstration project for target trial emulation; a publication from the National Institute of Health and Care Excellence (NICE) on the 1 year anniversary of their RWE framework; and a publication from NICE and Flatiron Health on the utility of US RWD for initial UK health technology assessment decision making.PMID:38179957 | PMC:PMC10842288 ...
Source: Journal of Comparative Effectiveness Research - January 5, 2024 Category: General Medicine Authors: Benjamin D Bray Sreeram V Ramagopalan Source Type: research

R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 14
J Comp Eff Res. 2024 Jan;13(1):e230189. doi: 10.57264/cer-2023-0189. Epub 2024 Jan 4.ABSTRACTIn this latest update we highlight: a publication from the US FDA regarding the definitions of real-world data (RWD) and real-world evidence (RWE); a publication from academic researchers on a demonstration project for target trial emulation; a publication from the National Institute of Health and Care Excellence (NICE) on the 1 year anniversary of their RWE framework; and a publication from NICE and Flatiron Health on the utility of US RWD for initial UK health technology assessment decision making.PMID:38179957 | DOI:10.57264/cer...
Source: Journal of Comparative Effectiveness Research - January 5, 2024 Category: General Medicine Authors: Benjamin D Bray Sreeram V Ramagopalan Source Type: research

Justifying the source of external comparators in single-arm oncology health technology submissions: a review of NICE and PBAC assessments
Conclusion: Although HTA bodies such as NICE and PBAC encourage that EC source justification should be provided in submissions, this review found that this is not typically implemented in practice. Guidance is needed to establish best practices as to how EC selection should be documented in HTA submissions.PMID:38174576 | DOI:10.57264/cer-2023-0140 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - January 4, 2024 Category: General Medicine Authors: Katherine Appiah Maria Rizzo Grammati Sarri Luis Hernandez Source Type: research

Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison
Conclusion: In the present study, we found that erenumab had a more favorable efficacy profile than rimegepant in reducing MMDs at month 1 and month 3 for migraine prevention. These results may help with decision-making in clinical practice and can be further validated in future clinical trials or real-world studies.PMID:38174577 | DOI:10.57264/cer-2023-0122 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - January 4, 2024 Category: General Medicine Authors: Ronan Mahon Santosh Tiwari Mirja Koch Matias Ferraris Keith A Betts Yan Wang Sophie Gao Pascal Proot Source Type: research

Justifying the source of external comparators in single-arm oncology health technology submissions: a review of NICE and PBAC assessments
Conclusion: Although HTA bodies such as NICE and PBAC encourage that EC source justification should be provided in submissions, this review found that this is not typically implemented in practice. Guidance is needed to establish best practices as to how EC selection should be documented in HTA submissions.PMID:38174576 | DOI:10.57264/cer-2023-0140 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - January 4, 2024 Category: General Medicine Authors: Katherine Appiah Maria Rizzo Grammati Sarri Luis Hernandez Source Type: research

Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison
Conclusion: In the present study, we found that erenumab had a more favorable efficacy profile than rimegepant in reducing MMDs at month 1 and month 3 for migraine prevention. These results may help with decision-making in clinical practice and can be further validated in future clinical trials or real-world studies.PMID:38174577 | DOI:10.57264/cer-2023-0122 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - January 4, 2024 Category: General Medicine Authors: Ronan Mahon Santosh Tiwari Mirja Koch Matias Ferraris Keith A Betts Yan Wang Sophie Gao Pascal Proot Source Type: research

Improved estimation of overall survival and progression-free survival for state transition modeling
Conclusion: A novel approach is defined which provides an alternative STM estimation method enabling improved fits to modeled endpoints, which can easily be extended to more complex model structures.PMID:38099516 | DOI:10.57264/cer-2023-0031 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - December 15, 2023 Category: General Medicine Authors: Peter C Wigfield Bart Heeg Mario Ouwens Source Type: research

Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting
Conclusion: In the first R/R setting, patients who used InO had significantly lower all-cause and ALL-related costs compared with patients who used Blina, in part driven by hospitalization patterns.PMID:38099517 | DOI:10.57264/cer-2023-0142 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - December 15, 2023 Category: General Medicine Authors: Alexander Russell-Smith Louise Murphy Amy Nguyen Cori Blauer-Peterson Marilou Terpenning Feng Cao Shiqiang Li Tim Bancroft Noah Webb Stephanie Dorman Richa Shah Source Type: research

Risk of long-term care admissions among Medicare beneficiaries treated with pimavanserin or quetiapine for Parkinson's disease psychosis in USA: a retrospective administrative claims database analysis
Conclusion: The 20% lower risk of LTCA (i.e., greater delay) with PIM versus QUE in this analysis may suggest that PIM should be started early for the treatment of PDP.PMID:38099518 | DOI:10.57264/cer-2023-0114 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - December 15, 2023 Category: General Medicine Authors: Krithika Rajagopalan Nazia Rashid Dilesh Doshi Source Type: research